Product Name :p21 (phospho-T145) polyclonal antibody
Reactivity :Human,Mouse,Rat
Application_all :IHC: 1:50~1:200
Background :It is now well established that cyclins play a positive role in promoting cell cycle transitions via their ability to associate with and activate their cognate cyclin-dependent kinases (Cdks). Cdk2 associates with cyclins A, D and E, and has been implicated in the control of the G1 to S phase transition in mammals. A novel Cdk-interacting protein, designated p21, Cip1 or WAF1, has been identified in cyclin A, cyclin D1, cyclin E and Cdk2 immunoprecipitates. p21 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk 2, cyclin E-Cdk2, cyclin D1-Cdk4 and cyclin D2-Cdk4 complexes. Expression of p21 is inducible by wildtype, but not mutant, p53. The mouse homolog of p21 is designated CAP20.
Product :Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Purification&Purity :The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Storage&Stability :Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :p-p21 (T145) polyclonal antibody detects endogenous levels of p21 protein only when phosphorylated at Thr145
Note :For research use only, not for use in diagnostic procedure.
Pathway :Cell Cycle Control G1 S Checkpoint,Cell Cycle G2 M DNA Damage Signaling Pathway,
Alternative Name :Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1
Immunogen :Synthetic phosphopeptide derived from human p21 around the phosphorylation site of Threonine 145.
Modification :Phosphorylation
